Carregant...
A Review of Interstitial Pneumonitis Caused by Elotuzumab Through Case Discussions and Academic Writings
Patients with relapsed or refractory multiple myeloma have undergone two or three previous therapies are now being treated with a humanized IgG1 monoclonal antibody elotuzumab (HuLuc63) that targets F7 signalling lymphocytic activation molecule F7 (SLAMF7)- a signalling lymphocytic activation molecu...
Guardat en:
| Publicat a: | Cureus |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Cureus
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7686952/ https://ncbi.nlm.nih.gov/pubmed/33251069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.11162 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|